Doctors choose endocrine or targeted therapy according to the molecular expression of the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2), which greatly improve the overall survival of BC patients. This evidence concerns the gene ERBB2 and breast cancer.